Group A streptococcal (GAS) diseases are a significant public health problem in both developing and developed countries. No vaccines are available for protection against GAS infections. Meetings supported by the National Institutes of Health and the World Health Organization have resulted in development of field protocols for standardized surveillance of GAS disease to obtain burden of disease data to: 1) compare data across geographic sites, 2) develop sample size estimates and endpoints for vaccine clinical trials, and 3) increase awareness and attract investment for vaccine development and introduction.
The field protocols were developed by working groups that included scientists and clinicians with expertise in GAS research and epidemiology from the United States and developing countries, representatives from the World Health Organization, and U.S. federal agencies (NIAID and the Centers for Disease Control and Prevention). These protocols have been implemented at NIAID-supported clinical sites in Mali (Africa), Leon (Nicaragua), Suva (Fiji), and Capetown (South Africa) to obtain epidemiological data that will be useful for designing future vaccine clinical trials. When all data from these clinical studies have been collected and analyzed, the protocols will be reviewed and updated as appropriate.
Last Updated February 28, 2010